Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 2/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.35 |
| ▸ | MGMT | P16455 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17570452 | 0.88 | TOP2A (0.41) | TOP2ASLC9A1GGPS1MGMTPTGS2 | |
| SCHEMBL3566504 | 0.86 | SLC9A1 (0.41) | TOP2ASLC9A1GGPS1ALDH1A1POLB | |
| SCHEMBL18163273 | 0.85 | GGPS1 (0.40) | TOP2ASLC9A1GGPS1MGMTADORA2A | |
| SCHEMBL24754052 | 0.84 | SLC9A1 (0.42) | TOP2ASLC9A1GGPS1PTGS2POLB | |
| SCHEMBL10079215 | 0.84 | SLC9A1 (0.42) | TOP2ASLC9A1GGPS1PTGS2POLB | |
| SCHEMBL24769808 | 0.83 | MGMT (0.32) | GGPS1MGMTPTGS2 | |
| SCHEMBL5656543 | 0.83 | GGPS1 (0.36) | TOP2ASLC9A1GGPS1MGMTADORA2A | |
| SCHEMBL10814469 | 0.82 | — | — | |
| SCHEMBL3546972 | 0.82 | GGPS1 (0.51) | TOP2ASLC9A1GGPS1MGMT | |
| Hydrochloric Acid SCHEMBL5655674 | 0.82 | MGMT (0.47) | TOP2ASLC9A1GGPS1MGMTADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833229-B2 | Labeling precursors with squaric acid coupling | SCV SPEZIAL-CHEMIKALIEN-VERTRIEBS GMBH (DE) | 2023-12-05 | — | — | US | disclosed |
| WO-2017059411-A9 | INHIBITORS OF MENAQUINONE BIOSYNTHESIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-2321323-B1 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTI-CANCER THERAPY | PF MEDICAMENT (FR) | 2013-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833229-B2 | Labeling precursors with squaric acid coupling | SCLY, SRRT, CS | TOP2A 1757/4885SLC9A1 711/4885GGPS1 759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.